The Next Generation of Antibody–Drug Conjugates in Oncology: Nature Medicine | August 2026

Introduction:

Antibody–drug conjugates (ADCs) have transformed cancer treatment by combining the precision of monoclonal antibodies with the potency of cytotoxic drugs, enabling targeted delivery of chemotherapy directly to tumour cells while minimising systemic toxicity. Following remarkable success in breast, gastric, lung, and other cancers, the field is rapidly evolving beyond first-generation ADCs. This review highlights the next wave of ADC innovation, focusing on improved drug design, novel payloads, biomarker-driven patient selection, and combination strategies that aim to overcome resistance and expand the clinical impact of ADCs.

Why was this review needed?

ADCs have become a major therapeutic platform across multiple solid tumors.

Resistance to current ADCs limits the durability of clinical benefit.

Advances in antibody engineering, linker chemistry, and payload design are rapidly reshaping ADC development.

The pace of ADC innovation now exceeds the capacity of traditional clinical trial models.

Personalized approaches are needed to match individual patients with the most effective ADC.

Key Takeaways:

Next-generation ADCs are being designed with improved antibodies, more stable linkers, optimized drug-to-antibody ratios (DAR), and more potent payloads to maximize efficacy while reducing toxicity.

Future ADCs will integrate multiple engineering advances within a single construct, rather than relying on a single innovation.

Biomarker-driven patient selection using multidimensional molecular profiling will become increasingly important for predicting ADC sensitivity and resistance.

Rational combinations with immune checkpoint inhibitors, targeted therapies, and other ADCs may enhance efficacy and overcome resistance mechanisms.

ADCs are expected to move earlier in the treatment pathway, including neoadjuvant and adjuvant settings, where they may improve cure rates.

Development of diverse ADC libraries with varying payloads, linker technologies, and drug-to-antibody ratios will facilitate individualized treatment based on tumor biology.

Novel clinical trial designs, translational research platforms, and advanced biomarker strategies will be essential to accelerate evaluation of the growing number of ADC candidates.

Clinical Impact:

Antibody–drug conjugates are evolving from targeted drug-delivery systems into highly engineered precision medicines. Future treatment decisions will likely depend not only on antigen expression but also on tumor biology, resistance mechanisms, and molecular biomarkers that predict response. The next generation of ADCs is expected to broaden the range of treatable cancers, improve efficacy, reduce toxicity, and support increasingly personalized oncology care.

Bottom Line:

The future of antibody–drug conjugates lies in smarter engineering, biomarker-guided patient selection, and rational combination therapies. As next-generation ADCs move into earlier stages of cancer treatment and become increasingly personalized, they are poised to redefine precision oncology across multiple tumor types.